Halozyme Therapeutics Inc.
NASDAQ:HALO 11:53:08 AM EDT
| Market Cap (Intraday) | 5.92B |
| Current PE | 25.90 |
| Forward PE | 25.22 |
| 2yr Forward PE | 16.13 |
| 10-Day MA | $41.52 |
| 50-Day MA | $41.33 |
| 200-Day MA | $43.83 |
Halozyme Therapeutics Inc. Stock, NASDAQ:HALO
11388 Sorrento Valley Road, San Diego, California 92121
United States of America
Phone: +1.858.794.8889
Number of Employees: 136
Description
Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development and commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. The firm products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.